Cimiracemoside CCAS# 256925-92-5 |
- Cimigenoside
Catalog No.:BCN5174
CAS No.:27994-11-2
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 256925-92-5 | SDF | Download SDF |
PubChem ID | 15541911 | Appearance | White powder |
Formula | C35H56O9 | M.Wt | 620.8 |
Type of Compound | Triterpenoids | Storage | Desiccate at -20°C |
Synonyms | Cimicifugoside M; Cimiracemoside C | ||
Solubility | Soluble in methanol; sparingly soluble in water | ||
SMILES | CC1CC2C(OC3(C1C4(CCC56CC57CCC(C(C7CCC6C4(C3O)C)(C)C)OC8C(C(C(CO8)O)O)O)C)O2)C(C)(C)O | ||
Standard InChIKey | BTPYUWOBZFGKAI-BKJHYQRZSA-N | ||
Standard InChI | InChI=1S/C35H56O9/c1-17-14-19-26(30(4,5)40)44-35(43-19)25(17)31(6)12-13-34-16-33(34)11-10-22(42-27-24(38)23(37)18(36)15-41-27)29(2,3)20(33)8-9-21(34)32(31,7)28(35)39/h17-28,36-40H,8-16H2,1-7H3/t17-,18+,19-,20+,21+,22+,23+,24-,25-,26+,27+,28-,31-,32-,33-,34+,35+/m1/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | The Cimicifuga racemosa extract Ze 450 and some of its components (23-epi-26-deoxyactein, protopine and cimiracemoside C) can reduce significantly body weight, plasma glucose, improve glucose metabolism and insulin sensitivity in diabetic ob/ob mice; suggests that part of the effects may be related to AMPK activation.Ze 450 may have utility in the treatment of type 2 diabetes. |
Targets | AMPK |
In vitro | Antidiabetic effects of the Cimicifuga racemosa extract Ze 450 in vitro and in vivo in ob/ob mice.[Pubmed: 25022210]Phytomedicine. 2014 Sep 25;21(11):1382-9.It was the aim of the present experiments to examine potential antidiabetic effects of the Cimicifuga racemosa extract Ze 450.
|
Structure Identification | J Agric Food Chem. 2006 May 3;54(9):3242-53.Evaluation of the botanical authenticity and phytochemical profile of black cohosh products by high-performance liquid chromatography with selected ion monitoring liquid chromatography-mass spectrometry.[Pubmed: 16637680]Black cohosh (Actaea racemosa L., syn. Cimicifuga racemosa L.) has become increasingly popular as a dietary supplement in the United States for the treatment of symptoms related to menopause, but the botanical authenticity of most products containing black cohosh has not been evaluated, nor is manufacturing highly regulated in the United States. |
Cimiracemoside C Dilution Calculator
Cimiracemoside C Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.6108 mL | 8.0541 mL | 16.1082 mL | 32.2165 mL | 40.2706 mL |
5 mM | 0.3222 mL | 1.6108 mL | 3.2216 mL | 6.4433 mL | 8.0541 mL |
10 mM | 0.1611 mL | 0.8054 mL | 1.6108 mL | 3.2216 mL | 4.0271 mL |
50 mM | 0.0322 mL | 0.1611 mL | 0.3222 mL | 0.6443 mL | 0.8054 mL |
100 mM | 0.0161 mL | 0.0805 mL | 0.1611 mL | 0.3222 mL | 0.4027 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- CCK Octapeptide, non-sulfated
Catalog No.:BCC5709
CAS No.:25679-24-7
- 3,2'-Dihydroxy-4,4'-dimethoxychalcone
Catalog No.:BCN7742
CAS No.:2567-65-9
- Cannabigerol
Catalog No.:BCN5127
CAS No.:25654-31-3
- Aponorhyoscine
Catalog No.:BCN1871
CAS No.:25650-56-0
- Nantenine
Catalog No.:BCN7788
CAS No.:2565-01-7
- Dactylorhin A
Catalog No.:BCN8217
CAS No.:256459-34-4
- Preisocalamendiol
Catalog No.:BCN5126
CAS No.:25645-19-6
- Ac2-12
Catalog No.:BCC5826
CAS No.:256447-08-2
- Schleicheol 2
Catalog No.:BCN5125
CAS No.:256445-68-8
- Schleicheol 1
Catalog No.:BCN4661
CAS No.:256445-66-6
- SEW 2871
Catalog No.:BCC7312
CAS No.:256414-75-2
- BAY 41-2272
Catalog No.:BCC7932
CAS No.:256376-24-6
- HU 308
Catalog No.:BCC5971
CAS No.:256934-39-1
- Lonicerin
Catalog No.:BCN8266
CAS No.:25694-72-8
- Tutin
Catalog No.:BCN5129
CAS No.:2571-22-4
- Homoarbutin
Catalog No.:BCN2680
CAS No.:25712-94-1
- KF 38789
Catalog No.:BCC5938
CAS No.:257292-29-8
- Velutin
Catalog No.:BCN5130
CAS No.:25739-41-7
- J 104129 fumarate
Catalog No.:BCC7389
CAS No.:257603-40-0
- CP 154526
Catalog No.:BCC7481
CAS No.:257639-98-8
- H-D-Glu(OBzl)-OH
Catalog No.:BCC2939
CAS No.:2578-33-8
- Pelitinib (EKB-569)
Catalog No.:BCC1118
CAS No.:257933-82-7
- Gemfibrozil
Catalog No.:BCC4783
CAS No.:25812-30-0
- LEP (116-130) (mouse)
Catalog No.:BCC1016
CAS No.:258276-95-8
Evaluation of the botanical authenticity and phytochemical profile of black cohosh products by high-performance liquid chromatography with selected ion monitoring liquid chromatography-mass spectrometry.[Pubmed:16637680]
J Agric Food Chem. 2006 May 3;54(9):3242-53.
Black cohosh (Actaea racemosa L., syn. Cimicifuga racemosa L.) has become increasingly popular as a dietary supplement in the United States for the treatment of symptoms related to menopause, but the botanical authenticity of most products containing black cohosh has not been evaluated, nor is manufacturing highly regulated in the United States. In this study, 11 black cohosh products were analyzed for triterpene glycosides, phenolic constituents, and formononetin by high-performance liquid chromatography-photodiode array detection and a new selected ion monitoring liquid chromatography-mass spectrometry method. Three of the 11 products were found to contain the marker compound cimifugin and not Cimiracemoside C, thereby indicating that these plants contain Asian Actaea instead of black cohosh. One product contained both black cohosh and an Asian Actaea species. For the products containing only black cohosh, there was significant product-to-product variability in the amounts of the selected triterpene glycosides and phenolic constituents, and as expected, no formononetin was detected.
Antidiabetic effects of the Cimicifuga racemosa extract Ze 450 in vitro and in vivo in ob/ob mice.[Pubmed:25022210]
Phytomedicine. 2014 Sep 25;21(11):1382-9.
INTRODUCTION: It was the aim of the present experiments to examine potential antidiabetic effects of the Cimicifuga racemosa extract Ze 450. METHODS: Ze 450 and some of its components (23-epi-26-deoxyactein, protopine and Cimiracemoside C) were investigated in vitro for their effects on AMP-activated protein kinase (AMPK) compared to metformin in HepaRG cells. Ze 450 (given orally (PO) and intraperitonally (IP)), metformin (PO) and controls were given over 7 days to 68 male ob/ob mice. Glucose and insulin concentrations were measured at baseline and during an oral glucose tolerance test (OGTT). RESULTS: Ze 450 and its components activated AMPK to the same extent as metformin. In mice, Ze 450 (PO/IP) decreased significantly average daily and cumulative weight gain, average daily food and water intake, while metformin had no effect. In contrast to metformin, PO Ze 450 virtually did not change maximum glucose levels during OGTT, however, prolonged elimination. Ze 450 administered PO and IP decreased significantly post-stimulated insulin, whereas metformin did not. HOMA-IR index of insulin resistance improved significantly after IP and PO Ze 450 and slightly after metformin. In summary, the results demonstrate that Ze 450 reduced significantly body weight, plasma glucose, improved glucose metabolism and insulin sensitivity in diabetic ob/ob mice. In vitro experiments suggest that part of the effects may be related to AMPK activation. CONCLUSIONS: Ze 450 may have utility in the treatment of type 2 diabetes. However, longer term studies in additional animal models or patients with disturbed glucose tolerance or diabetes may be of use to investigate this further.